GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide

Monday, 8 August 2022, 16:42:00
GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This
— Wallstreet:Online

Christopher Gent fined £80,000 by FCA for disclosing inside information

Friday, 5 August 2022, 13:05:04
UK regulator rules that businessman breached fiduciary duties by sharing ConvaTec information Sir Christopher Gent, the former chief executive of Vodafone and ex-chair of GlaxoSmithKline, has been fined £80,000 by the UK financial watchdog for disclosing inside information to shareholders while chair of the medical-devices maker ConvaTec. The Financial Conduct Authority (FCA) has fined Gent, one of the most prominent figures in British business, after ruling that he shared information relating to a revision of the financial performance of ConvaTec and plans for the retirement of its chief executive to senior individuals at two of the London-listed company’s biggest shareholders. Continue reading…
— The Guardian

UK watchdog fines veteran businessman Gent 80,000 pounds

Friday, 5 August 2022, 11:53:59
LONDON — Britain’s financial watchdog said on Friday it has fined Christopher Gent 80,000 pounds ($97,104) for unlawfully disclosing inside information in 2018 when he was non-executive chairman of medical technology company ConvaTec. A former CEO of Vodafone and former non-executive chairman of GlaxoSmithKline, the Financial Conduct Authority (FCA) said Gent disclosed information about an […]
— Financial Post

GSK plc – Consensus Indicates Potential 47.6% Upside

Wednesday, 3 August 2022, 12:47:13
GSK plc found using ticker (GSK) have now 3 analysts in total covering the stock. The consensus rating is ”Buy”. The range between the high target price and low target price is between 63.75 and 57.42 with a mean TP of 61.43. Now with the previous closing price of 41.63 this is indicating there is a potential upside of 47.6%. There is a 50 day moving average of 42.89 while the 200 day moving average is 43.85. The market capitalisation for the company is $84,612m. Visit the company website at: https://www.gsk.com [stock_market_widget type=”chart” template=”basic” color=”green” assets=”GSK” range=”6mo” interval=”1d” axes=”true” cursor=”true” api=”yf”] The potential market cap would be $124,855m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
— DirectorsTalk

GSK offers to buy back exchangeable senior notes

Wednesday, 3 August 2022, 10:25:56
GSK (GSK) said its unit GSK Finance is offering to buy back for cash any and all of its outstanding exchangeable senior notes due 2023.As of Aug
— Seeking Alpha